<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="4003">
  <stage>Registered</stage>
  <submitdate>6/07/2013</submitdate>
  <approvaldate>6/07/2013</approvaldate>
  <nctid>NCT01896635</nctid>
  <trial_identification>
    <studytitle>Faecal Microbiota Transplantation in Ulcerative Colitis</studytitle>
    <scientifictitle>Faecal Microbiota Transplantation for Chronic Active Ulcerative Colitis - A Randomised Double Blind Controlled Study of Efficacy &amp; Safety</scientifictitle>
    <utrn />
    <trialacronym>FOCUS</trialacronym>
    <secondaryid>FOCUS</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Ulcerative Colitis</healthcondition>
    <healthcondition>Inflammatory Bowel Disease</healthcondition>
    <conditioncode>
      <conditioncode1>Oral and Gastrointestinal</conditioncode1>
      <conditioncode2>Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Inflammatory and Immune System</conditioncode1>
      <conditioncode2>Other inflammatory or immune system disorders</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Oral and Gastrointestinal</conditioncode1>
      <conditioncode2>Inflammatory bowel disease</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Other interventions - FMT infusions
Other interventions - Placebo infusion

Active Comparator: FMT infusions - FMT infusions constituted from stool provided by healthy, screened donors

Placebo Comparator: Placebo arm - Placebo infusions


Other interventions: FMT infusions
Active FMT derived from healthy anonymous pre-screened donors

Other interventions: Placebo infusion
Placebo infusion not containing any donor microbial material

</interventions>
    <comparator />
    <control />
    <interventioncode>Other interventions interventions</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Composite Clinical remission &amp; Endoscopic remission / response as measured by Mayo subscores</outcome>
      <timepoint>8 weeks</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Clinical remission as measured by Mayo subscores</outcome>
      <timepoint>8 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Clinical response as measured by Mayo subscores</outcome>
      <timepoint>8 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Endoscopic healing as measured by UCEIS</outcome>
      <timepoint>8 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Treatment failure rate as defined by Mayo subscores</outcome>
      <timepoint>8 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Quality of life as measured by IBDQ</outcome>
      <timepoint>8 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Safety and tolerability as measured by adverse event data</outcome>
      <timepoint>8 weeks</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Ulcerative colitis &gt;3 months duration

          -  Active mild-moderate ulcerative colitis (Mayo 4-10)

          -  Ulcerative colitis of any extent except isolated proctitis &lt; 5cm

          -  Live within driving distance of clinical site (to attend multiple study visits)</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>75</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Pregnancy

          -  Active gastrointestinal infection

          -  Other gastrointestinal disease / comorbidities

          -  Prior colonic surgery

          -  Recent antibiotic or probiotic use

          -  Prednisone &gt; 20mg

          -  Monoclonal antibody immunosuppressive therapy</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2>The people administering the treatment/s</masking2>
    <masking3>The people assessing the outcomes</masking3>
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>1/11/2013</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>81</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/08/2016</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW,QLD</recruitmentstate>
    <hospital>St Vincent's Hospital - Sydney</hospital>
    <hospital>Bankstown-Lidcombe Hospital - Sydney</hospital>
    <hospital>Nambour General Hospital - Nambour</hospital>
    <postcode>2010 - Sydney</postcode>
    <postcode>2200 - Sydney</postcode>
    <postcode>4560 - Nambour</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other</primarysponsortype>
    <primarysponsorname>The University of New South Wales</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this study is to determine whether fecal microbiota transplantation (FMT) is
      safe and efficacious in the treatment of chronic active ulcerative colitis (UC) by conducting
      a randomised controlled trial</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01896635</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Hazel Mitchell, BSc PhD</name>
      <address>University of New South Wales</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>